HOME >> MEDICINE >> NEWS
Common osteoporosis treatment may help men with prostate cancer suffering from bone loss

SAN FRANCISCO, Feb. 25 Men with prostate cancer who experience bone loss from cancer treatment could benefit from a weekly oral therapy commonly given to women with osteoporosis, according to a study presented by the University of Pittsburgh Medical Center (UPMC) at the American Society of Clinical Oncology Prostate Cancer Symposium, Feb. 24 to 26 at the San Francisco Marriott. The study, abstract number 139, will be featured in a press program at the meeting, 7:30 a.m., Sunday, Feb. 26.

"In previous studies, we have determined that men who receive androgen deprivation therapy, a frequently used treatment for prostate cancer, suffer from severe drops in bone mass and are at an increased risk for fracture," said study principal investigator Susan Greenspan, M.D., professor of medicine, University of Pittsburgh and director, Osteoporosis Prevention and Treatment Center, UPMC. "In an attempt to mitigate these effects, we gave men using this therapy a once-weekly oral agent called alendronate that is commonly used to treat osteoporosis. We found that men who received it had significantly increased bone mass compared to those who did not receive the therapy."

The study included 112 men with prostate cancer with an average age of 71. After an average of two years androgen deprivation therapy for prostate cancer, only 9 percent of the men had normal bone mass, while 52 percent had low bone mass and 39 percent developed osteoporosis. To study the effect of alendronate on these men, they were randomized into two groups to receive either alendronate once a week through an orally administered pill or a placebo. At one year follow-up, bone mass in the spine and hip increased significantly in the men treated with alendronate, 4.9 percent and 2.1 percent respectively. By comparison, men in the placebo group had significant losses of bone mass in the spine and hip, 1.3 percent and .7 percent respectively. In addition, the therapy was well-tolerated and easily adm
'"/>


25-Feb-2006


Page: 1 2

Related medicine news :

1. Commonly used drug offers promise for premature babies
2. Commonly used pain medications do not prevent Alzheimers disease
3. Common anesthetic may induce cell death, generation of Alzheimers-associated protein
4. Common blood pressure drug treats muscular dystrophy in mice
5. Common PTSD drug is no more effective than placebo
6. Common cold may be just a fingertip away due to environmental contamination
7. Commonwealth Fund commission says the US health care system needs thorough transformation
8. Commonly recommended sedative does not improve infant sleep
9. Common asthma inhaler causing deaths, researchers assert
10. Common painkillers associated with increased risk of first hospital admission for heart failure
11. Commonly used blood pressure medication prevents aortic aneurysm in mice with Marfan syndrome

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/26/2017)... ... July 26, 2017 , ... Evergreen Healthcare ... of their continued efforts to provide innovative offerings to their healthcare partners. These ... and build dynamic, high-performing teams to address healthcare IT’s biggest challenges. , “Adding ...
(Date:7/26/2017)... ... 2017 , ... It's time to sign up for the new One-A-Month Essential Oil ... Heshelow, founder of Sublime Naturals and author of numerous books on essential oils. , ... by the 5th. , Two items are included in the December mailing. ...
(Date:7/26/2017)... ... July 26, 2017 , ... IDC-Eating Disorder Care is excited to ... located in Royal Oak, Michigan. IDC, formerly known as Inner Door Center, ... the highest standards in the field of eating disorder treatment in the state of ...
(Date:7/26/2017)... ... July 26, 2017 , ... The number of adults 65 years or older ... to improve asthma control in the population are not well described. In a study ... an official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), researchers ...
(Date:7/25/2017)... Raleigh, NC (PRWEB) , ... July 25, 2017 ... ... provides asset protection assistance and finance management services to communities across North Carolina, ... Bladder Cancer Advocacy Network to raise community support for the ongoing fight against ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... BEACH, Fla. , July 26, 2017 ... of enrollment of our clinical trial evaluating Altemia TM ... Cell Anemia (SCA) and Sickle Cell Disease (SCD). The ... to evaluate the efficacy and safety of Altemia TM ... trial is conducted under US IND 125274. ...
(Date:7/25/2017)... and CAMBRIDGE, Massachusetts , July ... specializing in repurposing drugs to treat rare nervous system diseases, ... to clinically develop and market the drug SOM0226 against transthyretin ... drug achieved very promising results in a Phase 2 study ... A new office in the United States ...
(Date:7/24/2017)... 2017 IBM (NYSE: IBM ) has been ... Solid-State Arrays (SSA) for the fourth year in a row. ... Gartner, "Vendors in the Leaders quadrant have the highest scores ... vendor in the Leaders quadrant has the market share, credibility, ... of new technologies. These vendors demonstrate a clear understanding of ...
Breaking Medicine Technology:
Cached News: